Many people die from cancer, drug-resistant bacteria and other infectious diseases. The demand for new and efficient drugs has never been higher, and will only keep on growing.
Every day, our AI platform, AI-Immunology™, brings us closer to a future where we can treat a wide range of critical diseases.
This is why our purpose is: Decoding the human immune system to develop novel vaccines for cancer and infectious diseases with our AI-Immunology™ platform.
AI-Immunology™ harnesses the power of artificial intelligence to decode the human immune system and develop novel drug candidates for cancer and infectious diseases. With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development both independently and in collaboration with partners.
At Evaxion, we stand at the forefront of the biotechnology industry with our advanced use of artificial intelligence and machine learning technologies to model the immune system. However, our strength lies not only in our technological innovations but also in our comprehensive, multidisciplinary approach.
Our multidisciplinary team operates within state-of-the-art facilities to pioneer the design and development of personalized and precision vaccine candidates tailored to meet specific disease signatures and partners’ needs.
Our robust AI prediction models are specifically trained in the fields of cancer and infectious diseases, offering a clinically validated predictive capability that sets us apart in the biotech space. This precision allows for the rapid discovery of therapeutically relevant and delivery modality agnostic vaccine targets within 24 hours, enabling us to meet a wide range of specifications and requirements.
years of development
Initial Public Offering (IPO) on U.S. Nasdaq
in-house developed assets between preclinical and phase 2
preclinical studies
